NCT06711068

Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target Therapy

Cohort Study of Adjuvant Chemotherapy Combined With Targeted Therapy for Intermediate Risk HER2 Positive and Lymph Node Negative Early Breast Cancer

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 8,077 (estimated)
• Sponsor: Shu Wang · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

Human epidermal growth factor receptor 2 (HER2) positive breast cancer is a molecular subtype with high malignancy and easy recurrence and metastasis. The emergence of HER2 targeted drugs has greatly improved the prognosis and survival of such patients. At present, for HER2 positive breast cancer patients with negative lymph nodes, chemotherapy drugs combined with trastuzumab is the current standard treatment scheme, and in most cases, chemotherapy uses a combination of two drugs, while the main beneficiaries of the trastuzumab and pertuzumab are concentrated in the group of patients with positive lymph nodes. Can targeted therapy be used to reduce the progression of chemotherapy and further achieve efficient and low toxicity strategies. It is planned to explore the efficacy and safety of T1-T2, HER2 positive early breast cancer patients with negative lymph nodes to achieve chemotherapy reduction based on risk stratification.

Conditions

• HER2-positive Breast Cancer

Timeline

• Start date: 2019-01-01
• Primary completion: 2031-12-31
• Completion: 2031-12-31
• First posted: 2024-12-02
• Last updated: 2024-12-02

Locations

1 site across 1 country: China